

## **Retired Policy**

## Germline Genetic Testing for Gene Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk (CHEK2, ATM, and BARD1)

Policy # 00504 Original Effective Date: 07/20/2016 Retired Date: 07/01/2024

Germline Genetic Testing for Gene Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk (CHEK2, ATM, and BARD1) was retired effective 07/01/2024.

A retired medical policy is no longer active and is not utilized for coverage eligibility determination or claims processing as of the retired date.

This medical policy is being retired as a part of the collaborative partnership with Carelon MBM Genetic Testing Program. Carelon will provide genetic testing management services to ensure enforcement of genetic testing policies effective 07/01/2024.

©2024 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.